Practical Guide to Best Practices in Alcohol-Associated Liver Disease

Vinay Jahagirdar; Elina Stoffel; Kaanthi Rama; Alexandre Louvet; Gene Im; Juan P. Arab

doi:10.1055/a-2772-7248

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis
DOI: 10.1055/a-2772-7248

Review Article

Practical Guide to Best Practices in Alcohol-Associated Liver Disease

Autor*innen

Vinay Jahagirdar^†

¹Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States
Elina Stoffel^†

²Center for Liver Disease and Transplantation, Division of Digestive and Liver Diseases, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States
Kaanthi Rama

¹Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States
Alexandre Louvet^‡

³Service des maladies de l'appareil digestif, CHU Lille, Lille, Hauts-de-France, France
Gene Im^‡

²Center for Liver Disease and Transplantation, Division of Digestive and Liver Diseases, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States
Juan P. Arab^‡

¹Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States

Abstract

Keywords

alcohol-related liver disease - alcohol-associated hepatitis - acute-on-chronic liver failure - alcohol use disorder - steatotic liver disease - noninvasive fibrosis assessment - liver transplantation

Volltext

Referenzen

References
1 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78 (06) 1966-1986
2 Crabb DW, Bataller R, Chalasani NP. et al; NIAAA Alcoholic Hepatitis Consortia. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology 2016; 150 (04) 785-790
3 Moreau R, Jalan R, Gines P. et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437 , 1437.e1–1437.e9
4 Bajaj JS, O'Leary JG, Reddy KR. et al; North American Consortium For The Study Of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology 2014; 60 (01) 250-256
5 Aggarwal R, Farag S, Martin G, Ashrafian H, Darzi A. Patient perceptions on data sharing and applying artificial intelligence to health care data: cross-sectional survey. J Med Internet Res 2021; 23 (08) e26162
6 Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020; 71 (01) 306-333
7 European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 2018; 69 (01) 154-181
8 Singal AK, Mathurin P. Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 2021; 326 (02) 165-176
9 Bataller R, Arab JP, Shah VH. Alcohol-associated hepatitis. N Engl J Med 2022; 387 (26) 2436-2448
10 Kalinowski A, Humphreys K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 2016; 111 (07) 1293-1298
11 Drink Size Calculator. [cited 2025 May 5]; Accessed December 22, 2025 at: https://rethinkingdrinking.niaaa.nih.gov/tools/calculators/drink-size-calculator
12 Torp N, Israelsen M, Nielsen MJ. et al. Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3). Liver Int 2022; 42 (01) 92-101
13 Lieber CS, Jones DP, Decarli LM. Effects of prolonged ethanol intake: production of fatty liver despite adequate diets. J Clin Invest 1965; 44 (06) 1009-1021
14 Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 1990; 322 (02) 95-99
15 Whitfield JB, Schwantes-An TH, Darlay R. et al; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol 2022; 76 (02) 275-282
16 Jophlin LL, Singal AK, Bataller R. et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol 2024; 119 (01) 30-54
17 Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol 2017; 112 (01) 18-35
18 Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol 2019; 114 (08) 1202-1218
19 Curry SJ, Krist AH, Owens DK. et al; US Preventive Services Task Force. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 320 (18) 1899-1909
20 Moyer VA. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement. Ann Intern Med 2013; 159 (03) 210-218
21 Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician 2009; 79 (03) 203-208
22 Murali AR, Attar BM, Katz A, Kotwal V, Clarke PM. Utility of platelet count for predicting cirrhosis in alcoholic liver disease: model for identifying cirrhosis in a US population. J Gen Intern Med 2015; 30 (08) 1112-1117
23 Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342 (17) 1266-1271
24 Cerović I, Mladenović D, Ješić R. et al. Alcoholic liver disease/nonalcoholic fatty liver disease index: distinguishing alcoholic from nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013; 25 (08) 899-904
25 Snozek CLH, Kinard TN, Alegria KN, Jannetto PJ, Langman LJ. Artificial elevation of phosphatidylethanol due to red blood cell transfusion. Clin Biochem 2023; 120: 110651
26 Arab JP, Díaz LA, Rehm J. et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol 2025; 82 (04) 744-756
27 Vaz J, Nasr P, Helander A. et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol 2025; 83 (05) 1011-1022
28 Thorhauge KH, Semmler G, Johansen S. et al; Microb-Predict, Galaxy and MicrobLiver consortia. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. J Hepatol 2024; 81 (01) 23-32
29 Rasmussen DN, Thiele M, Johansen S. et al; GALAXY, MicrobLiver consortia. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol 2021; 75 (05) 1017-1025
30 Sterling RK, Duarte-Rojo A, Patel K. et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2025; 81 (02) 672-724
31 Nguyen-Khac E, Thiele M, Voican C. et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2018; 3 (09) 614-625
32 Connoley D, Patel PJ, Hogan B. et al. The enhanced liver fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. BMC Gastroenterol 2021; 21 (01) 268
33 Calès P, Oberti F, Michalak S. et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42 (06) 1373-1381
34 Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology 2018; 154 (05) 1369-1379
35 Israelsen M, Rungratanawanich W, Thiele M, Liangpunsakul S. Non-invasive tests for alcohol-associated liver disease. Hepatology 2024; 80 (06) 1390-1407
36 de Lédinghen V, Beau P, Mannant PR. et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. Dig Dis Sci 1997; 42 (03) 536-541
37 Al-Obaid LN, Bazarbashi AN, Cohen ME. et al. Enteric tube placement in patients with esophageal varices: Risks and predictors of postinsertion gastrointestinal bleeding. JGH Open 2019; 4 (02) 256-259
38 Lai JC, Tandon P, Bernal W. et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 74 (03) 1611-1644
39 Singer P, Blaser AR, Berger MM. et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019; 38 (01) 48-79
40 Singal AK, Wong RJ, Dasarathy S. et al. ACG clinical guideline: malnutrition and nutritional recommendations in liver disease. Am J Gastroenterol 2025; 120 (05) 950-972
41 Association AP. Diagnostic and statistical manual of mental disorders: DSM-5. 2013. American Psychiatric Association;
42 Díaz LA, König D, Weber S. et al. Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. Lancet Gastroenterol Hepatol 2025; 10 (05) 475-490
43 European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021; 75 (03) 659-689
44 Im GY, Kim-Schluger L, Shenoy A. et al. Early liver transplantation for severe alcoholic hepatitis in the United States–a single-center experience. Am J Transplant 2016; 16 (03) 841-849
45 De Gottardi A, Spahr L, Gelez P. et al. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med 2007; 167 (11) 1183-1188
46 Rutledge SM, Nathani R, Wyatt BE. et al. Age added to MELD or ACLF predicts survival in patients with alcohol-associated hepatitis declined for liver transplantation. Hepatol Commun 2024; 8 (09) e0514
47 Sersté T, Cornillie A, Njimi H. et al. The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis. J Hepatol 2018; 69 (02) 318-324
48 Bajaj JS, O'Leary JG, Lai JC. et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol 2022; 117 (02) 225-252
49 Louvet A, Thursz MR, Kim DJ. et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials. Gastroenterology 2018; 155 (02) 458-468.e8
50 Arab JP, Díaz LA, Baeza N. et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study. J Hepatol 2021; 75 (05) 1026-1033
51 Parker R, Cabezas J, Altamirano J. et al. Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis. Clin Gastroenterol Hepatol 2022; 20 (02) e289-e297
52 Louvet A, Naveau S, Abdelnour M. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45 (06) 1348-1354
53 Mathurin P, O'Grady J, Carithers RL. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60 (02) 255-260
54 Nguyen-Khac E, Thevenot T, Piquet MA. et al; AAH-NAC Study Group. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med 2011; 365 (19) 1781-1789
55 Tandon P, Walling A, Patton H, Taddei T. AGA clinical practice update on palliative care management in cirrhosis: expert review. Clin Gastroenterol Hepatol 2021; 19 (04) 646-656.e3
56 Farokhnia M, Tazare J, Pince CL. et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J Clin Invest 2025; 135 (09) e188314
57 Hendershot CS, Bremmer MP, Paladino MB. et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 2025; 82 (04) 395-405
58 Flippo KH, Trammell SAJ, Gillum MP. et al. FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit. Cell Metab 2022; 34 (02) 317-328.e6
59 Díaz LA, Collier S, Yin J, Loomba R. Safety and tolerability of injectable extended-release naltrexone for the management of alcohol use disorder in advanced alcohol-associated liver disease. Aliment Pharmacol Ther 2025; 62 (07) 692-698
60 McPheeters M, O'Connor EA, Riley S. et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA 2023; 330 (17) 1653-1665